Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness by Combinations of Virus and Host Genes gives a comprehensive overview on the impact of using naturally or intentionally attenuated viruses - which are apathogenic to people - to control viral diseases and cancer. It examines the potential of exploiting, developing, and using apathogenic viruses as therapeutic tools. Sections cover the COVID-19 pandemic and the need for a post-Infection Plan B to combat SARS-CoV-2 infections as gaps in testing and vaccination create the perfect conditions for a new variant of concern to emerge.
More generally, the book also provides specific examples of the use of apathogenic viruses to treat other infectious diseases. It discusses the process of manufacturing viral therapies and how infectious disease treatments can be repurposed to improve other therapies like for cancer. With contribution from an international group of contributors, Leveraging Viruses for the Treatment of Viral Diseases and Cancer is useful references for those engages in study and development of infectious diseases and ways to combat them.
More generally, the book also provides specific examples of the use of apathogenic viruses to treat other infectious diseases. It discusses the process of manufacturing viral therapies and how infectious disease treatments can be repurposed to improve other therapies like for cancer. With contribution from an international group of contributors, Leveraging Viruses for the Treatment of Viral Diseases and Cancer is useful references for those engages in study and development of infectious diseases and ways to combat them.
Table of Contents
1. The Impact of Viral Creativity on the Evolution of Cellular Genes2. Our Antiviral Defense Comes from Viruses
3. Exploiting Viral Interference for Therapy
4. Fighting Fire with Fire: Vaccine Viruses to Control Viral Diseases
5. A Post-Infection Plan B to Complement COVID-19 Vaccination
6. Live Viral Vaccines Can Temporarily Protect Against COVID-19
7. Reduced Mortality Among HIV Infected Patients Coinfected with a Common Human Virus
8. Breakthrough Infection can be Achieved in the Presence of Neutralizing Antibodies by Multiple Administrations of Viruses
9. Safety and Regulatory Hurdles of Viral Therapy
10. Simplicity and Affordability of Manufacturing the Infectious Bursal Disease Virus (IBDV)
11. Three Out Of Four New Diseases are Zoonotic: Neglected Pandemic Threats in the United States
12. The Impact of Conventional Acyclovir Complemented with Immunostimulatory IBDV on the Crusting Time of Shingles
13. Combination of IBDV With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus Infections
14. Need for Further Research Providing Cheap and Effective Therapies for COVID-19
15. Repurposing Infectious Diseases Vaccines to Improve Cancer Therapy
